Steve Goldman is Professor of Neuroscience and Neurology at both the University of Copenhagen, and the University of Rochester Medical Center (URMC). At Copenhagen, he is Co-Director of its Center for Translational Neuromedicine and a consultant neurologist at Copenhagen University Hospital. At Rochester, he is the URMC Distinguished Professor of Neuroscience and Neurology, co-directs its Center for Translational Neuromedicine, and also holds the Dean Zutes Chair in Biology of the Aging Brain. Goldman moved in part to Copenhagen in 2014 from Rochester, where he has been since 2003. Before moving to Rochester, where he served as chairman of its neurology department from 2008-12, he was the Cummings Professor of Neurology at Weill Medical College of Cornell. A summa cum laude graduate of the University of Pennsylvania, he obtained his PhD with Fernando Nottebohm at Rockefeller University in 1983, and his MD from Cornell in 1984. Goldman did his residency in neurology at New York Hospital-Cornell and the Memorial Sloan-Kettering Cancer Center. Goldman is interested in cell genesis and regeneration in the adult brain, with a focus on the use of stem and progenitor cells in both modeling and treating demyelinating and neurodegenerative diseases, including targets as diverse as progressive multiple sclerosis, the leukodystrophies, Huntington Disease and schizophrenia. He also has a strong interest in the conversion of resident stem cells into brain cancers; clinically, he is additionally board certified in neuro-oncology. Goldman has published over 225 papers in his field, most as first or senior author, along with over 25 patents. He is a recipient of the Jacob Javits Neuroscience Investigator Award of the NIH, and the Novo Nordisk Foundation Laureate Award. He has been elected to the Academia Europaea, the Association of American Physicians, American Society for Clinical Investigation, and American Neurological Association, and has served on the FDA Cellular, Tissue and Gene Therapy Advisory Committee. His is a co-founder of Oscine Therapeutics, and his work is currently supported by NIMH, NINDS, the Adelson Medical Research Foundation, the ALS Association, CHDI, and the Lundbeck and Novo Nordisk Foundations.
« Go Back